Krystal Biotech (NASDAQ:KRYS) Now Covered by Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a research note released on Wednesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $245.00 target price on the stock.

Other analysts have also issued research reports about the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. HC Wainwright reissued a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Citigroup boosted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $220.00.

Krystal Biotech Price Performance

KRYS traded up $1.00 during trading on Wednesday, reaching $179.93. The company had a trading volume of 216,319 shares, compared to its average volume of 265,707. The business's fifty day moving average price is $161.18 and its 200 day moving average price is $174.57. The company has a market cap of $5.18 billion, a P/E ratio of 60.18 and a beta of 0.87. Krystal Biotech has a 12 month low of $141.72 and a 12 month high of $219.34.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm's revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.30 earnings per share. As a group, sell-side analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company's stock.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently bought and sold shares of KRYS. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Krystal Biotech in the fourth quarter worth about $3,634,000. GF Fund Management CO. LTD. bought a new position in shares of Krystal Biotech in the fourth quarter worth about $95,000. Palisades Investment Partners LLC lifted its holdings in shares of Krystal Biotech by 9.3% in the fourth quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company's stock worth $6,341,000 after acquiring an additional 3,436 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of Krystal Biotech by 23.0% in the fourth quarter. Woodline Partners LP now owns 221,102 shares of the company's stock worth $34,638,000 after acquiring an additional 41,287 shares during the last quarter. Finally, Soleus Capital Management L.P. lifted its holdings in shares of Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after acquiring an additional 141,400 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).